Hong Kong will resume administering the coronavirus vaccine developed by Pfizer and BioNTech on Monday following a 12-day suspension over packaging defects detected in one batch
HONG KONG — Hong Kong will resume administering the coronavirus vaccine developed by Pfizer and BioNTech on Monday following a 12-day suspension over packaging defects detected in one batch, officials said.
An additional 300,000 doses of the vaccine are expected to arrive on Friday, Civil Service Secretary Patrick Nip said Thursday.
Health officials said an investigation by BioNTech found no safety issues in the batch with packaging defects for some vials, as well as in a separate, unused batch of the vaccine.
Random checks will also be stepped up to ensure that vaccine packaging is safe, she said.
Residents who missed their vaccine appointments due to the suspension will be rescheduled. Those waiting to receive their second doses will have appointments within the first few days of the resumption, officials said.
The packaging defects included loose caps and leakage from some bottles. Prior to the suspension, about 151,000 people had received the Pfizer vaccine in the city.
The suspension was a further blow to the city’s struggling vaccine drive. Since vaccinations began in February, only about 6% of the population has signed up and received shots compared to over 16% in Singapore, which started vaccinations only several days earlier.
Apart from the Pfizer vaccine, Hong Kong residents have the option to receive Chinese-made Sinovac shots, although acceptance of that vaccine has fallen after reports that several people with chronic illnesses died after getting it.
Hong Kong officials say the deaths were not directly linked to the vaccine, but widespread distrust of the government and of Beijing means fewer residents are willing to be inoculated with the Sinovac shots.
Get more stuff like this
Subscribe to our mailing list and get interesting stuff and updates to your email inbox.